Second-line Weekly Nab-paclitaxel Noninferior to Paclitaxel for Gastric Cancer

New research out of The Lancet Gastroenterology & Hepatology journal shows that weekly nab-paclitaxel was noninferior to weekly solvent-based paclitaxel as second-line treatment for patients with advanced gastric cancer.